Increasing Accuracy in Prediction & Diagnosis of Cardiovascular Diseases to Spur Growth of Cardiac Biomarkers
Increasing consumer awareness, coupled with commercialization of increasingly accurate cardiac biomarkers for diagnosis of various cardiovascular diseases (CVD), rising incidence of CVD itself, and robust demand for remote or point-of-care cardiac tests are poised to drive the global market for Cardiac Biomarkers to reach about US$10 billion by 2024 . Biomarkers emerged as an important diagnostic tool for cardiac diseases because of their precision in detection of CVD-associated risks. Cardiac biomarkers are typically released into the blood, following an adverse cardiac event, and their detection in blood helps to diagnose the corresponding CVD event. This early detection and diagnosis is extremely crucial for combating cardiovascular disease and brings down the associated costs for treatment. Because CVD is a major cause of mortality worldwide, biomarkers evolved as an invaluable tool for diagnosis and prognosis of myocardial infarction and cardiac failure, thereby driving grow...